

Lichen butyrolactone derivatives disrupt oral bacterial membrane

Alaa Sweidan, Imen Smida, Marylene Chollet-Krugler, Aurélie Sauvager, Julien Vallet, Nicolas Gouault, Nolwenn Oliviero, Zohreh Tamanai-Shacoori, Agnès Burel, Pierre van de Weghe, et al.

▶ To cite this version:


Alaa Sweidan, Imen Smida, Marylene Chollet-Krugler, Aurélie Sauvager, Julien Vallet, et al.. Lichen butyrolactone derivatives disrupt oral bacterial membrane. Fitoterapia, 2019, 137, pp.104274. 10.1016/j.fitote.2019.104274 . hal-02280840

HAL Id: hal-02280840 https://univ-rennes.hal.science/hal-02280840


Submitted on 11 Feb2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.


S. gordonii




Butyrolactone derivatives





S. gordonii





Membrane disruption





P. gingivalis

P. gingivalis

Lichen butyrolactone derivatives disrupt oral bacterial membrane

2

- Alaa Sweidan ^{a, c}, Imen Smida ^a, Marylène Chollet-Krugler ^b, Aurélie Sauvager ^b, Julien
 Vallet ^b, Nicolas Gouault ^b, Nolwenn Oliviero ^a, Zohreh Tamanai-Shacoori ^a, Agnès Burel ^e,
 Pierre van de Weghe ^d, Ali Chokr ^c, Sophie Tomasi ^b, Latifa Bousarghin ^{a, *}
- ^a INSERM, Univ. Rennes, INRA, CHU Rennes, Nutrition Metabolisms and Cancer
 (NuMeCan), UMR-1241, Biosit, MRic/ISFR, Rennes, France.
- 9 ^b UMR CNRS 6226, Institut des Sciences Chimiques de Rennes, Equipe CORINT, Chimie
- 10 Organique et Interfaces, Univ. Rennes 1, Univ. Bretagne Loire, 2 Avenue du Pr. Léon
- 11 Bernard, F-35043 Rennes, France
- 12 ^c Laboratory of Microbiology, Department of Life and Earth Sciences, Faculty of Sciences I,
- 13 Lebanese University, Hadath Campus, Beirut, Lebanon
- ¹⁴ ^d Inserm U1242, Chemistry Oncogenesis Stress Signaling (COSS), Univ. Bretagne Loire, 2
- 15 Avenue du Pr. Léon Bernard, F-35043 Rennes, France
- ^e Plateforme microscopie électronique MRic, Campus Santé, Rennes 1, France
- 17
- 18 * Corresponding author. Bousarghin Latifa, U-1241 INSERM-INRA, Equipe CIMIAD, Univ.
- 19 Rennes 1, SFR Biosit, Université Européenne de Bretagne, Université de Rennes 1, 2 Avenue
- 20 du Professeur Léon Bernard, 35043 Rennes, France.
- 21
- 22 Tel.: (33) 02 23 23 48 98
- 23 Fax: (33) 02 23 23 49 13
- 24 E-mail: latifa.bousarghin@univ-rennes1.fr

- 26
- 27
- 28
- 29
- 30

31 Abstract

We have previously demonstrated that out of the butyrolactones series synthesized based on the natural lichen metabolite lichesterinic acid, compound (B-13) was the most effective against oral bacteria. However, its antibacterial mechanism is still unknown. In this study, we have investigated its bacterial localization by synthesizing a fluorescently labeled **B-13** with NBD while maintaining its antibacterial activity. We showed that this compound binds to Streptococcus gordonii cell surface, as demonstrated by HPLC analysis. By adhering to cell surface, B-13 induced cell wall disruption leading to the release of bacterial constituents and consequently, the death of S. gordonii, a Gram-positive bacterium. A Gram-negative counterpart, Porphyromanas gingivalis, showed also cracked and ruptured cells in the presence of B-13. Besides, we also demonstrated that the analog of B-13, B-12, has also induced disruption of *P. gingivalis* and *S. gordonii*. This study revealed that butyrolactones can be considered as potent antibacterial compounds against oral pathogens causing medical complications. Keywords: Lichen; Butyrolactone; Streptococcus gordonii; Porphyromanas gingivalis; cell wall


62 1. INTRODUCTION

Treatment of infections with antibiotics reduces morbidity; however, the erroneous or unsuitable antibiotic can lead to the emergence of resistant pathogenic bacteria [1]. Facing this worldwide concern, alternative antimicrobial candidates against multidrug-resistant bacteria were developed.

The new drugs, which are of natural origin, are capable of surpassing the bacterial resistance mechanisms [2]. Among the natural sources is the association of fungus and alga and/or cyanobacterium forming a symbiotic organism named lichen which produces more than 1000 distinct secondary metabolites. They were shown to be effective against sensitive and several multi-drug resistant bacterial strains [3–6].

72 Among the bacteria sensitive to lichen secondary metabolites, we have previously described that the synthesized butyrolactone analogs, B-13 and B-12 (Fig. 1), can inhibit the 73 74 growth of Streptococcus gordonii [7]. S. gordonii is a member of the viridans streptococci large category. In the oral cavity, S. gordonii adheres to the salivary pellicle which coats the 75 76 teeth, proliferates and excretes an extracellular polysaccharide matrix protecting their developing microcolony on which late colonizers will adhere. The sites provided by S. 77 78 gordonii are bound by Porphyromonas gingivalis and form a highly pathogenic complex 79 microbial community [8], [9]. S. gordonii, as a pioneer initial colonizer, initiates the formation of dental plaques contributing in turn to the onset of dental caries and periodontal 80 diseases as well as their progression [10]. Inhibiting S. gordonii might block the successive 81 steps leading to acute oral diseases and introduce new antibiotics that might be able to 82 prevent and treat the periodontal diseases. 83

84



85

Fig. 1. Chemical structures of B-12, B-13, and B-13 NBD.

The most common way of antimicrobial killing is triggered by disruption of the 87 cytoplasmic membrane. The bacterial cell membrane is responsible for many essential 88 functions: transport, osmoregulation and respiration processes, biosynthesis and cross-linking 89 of peptidoglycan, and synthesis of lipids. It is doubtless that for all these functions, 90 membrane integrity is absolutely necessary, and its disturbance can directly or indirectly 91 cause metabolic dysfunction and cell death. Alternative mechanisms of action include 92 antimicrobial translocation into the cytoplasm where they interfere with metabolic processes, 93 such as protein synthesis or DNA replication [11]. All of these modes of action have in 94 95 common that the bacterial membrane will be severely damaged in the end leading to cell death. One of the most validated targets for antibacterial therapy is the enzymes of 96 peptidoglycan biosynthesis. This biosynthesis is a complex process involving numerous steps 97 in the cytoplasm and the inner and outer leaflets of the cytoplasmic membrane [12], [13]. 98

Antimicrobials acting at the cell wall level are the most selective compared to other 99 100 antibiotics. In contrast to all types of antibiotics, the cell wall-targeting ones as the butyrolactones may escape from a bacterial resistant strategy in treating the oral biofilms. 101 102 Since the bacteria will grow significantly lower in its biofilm phase, thus, these metabolically reduced-activity bacteria regarding their biosynthesis of proteins, RNA, DNA, 103 peptidoglycan, and folic acid, will be less inhibited by the antibiotics targeting these 104 processes such as ribosome and DNA topoisomerases inhibitors [14]. For example, 105 Enterococcus faecalis oral biofilms have been shown to require very high concentrations of 106 antibiotics such as ampicillin and vancomycin (peptidoglycan synthesis inhibitor), and 107 108 linezolid (protein synthesis inhibitor) [15,16]. However, targeting the cell wall can be by targeting the synthesis of its components as peptidoglycan or it can be by binding directly to 109 the bacterial membrane bilayer thereby disrupting physically its integrity and its functions. 110 Hurdle et al. has mentioned also that the antimicrobials can target either the bacterial 111 membrane organization or the functions of membrane-associated respiratory enzymes [14]. 112

113

In this study, we investigated the mechanisms of action of butyrolactone analog B-13 on two oral bacteria implicated in periodontal diseases: S. gordonii and P. gingivalis. We 114 have also compared its mechanism to another butyrolactone analog (B-12). 115

- 116
- 117
- 118

119 2. Material and Methods

120 2.1. General chemistry

All reagents of high quality were purchased from commercial suppliers and used without 121 further purification. IR spectra were obtained with PerkinElmer UATR Two infrared 122 spectrophotometer. ¹H (300 MHz) and ¹³C (75 MHz) NMR spectra were performed on a 123 Bruker GMX 300 spectrometer. Chemical shifts were referenced to the residual solvent signal 124 (CDCl₃: $\delta_{\rm H}$ = 7.26, $\delta_{\rm C}$ = 77.16). The δ values are given in parts per million (ppm), and the 125 coupling constants (J values) are given in Hertz (Hz). The multiplicity of the signals is 126 reported as s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet). ESI-HRMS were 127 128 carried out on a Bruker MicroTof QII spectrometer for electrospray ionization at the CRMPO (Centre Régional de Mesures Physiques de l'Ouest), University of Rennes 1. Elemental 129 analyses were performed on a microanalyzer Flash EA1112 CHNS/O Thermo Electron at the 130 CRMPO. Reactions were monitored by TLC on Merk 60 F254 (0.25 mm) plates which were 131 visualized by UV detection or sprayed with KMNO₄ solutions, then heated. Log P values of 132 the compounds B-12, B-13 and the probe B-13 NBD have been calculated using ALOGPS 2.1 133 software. 134

135

- **B-13** and **B-12** derivatives described previously were used in this study [7]. Calculated log P = 7.29 (**B-12**) and 7.67 (**B-13**)
- 140

142 *tert-butyl ester 2:*

This compound was prepared as published [17]. Yield: 70%; red viscous oil. ¹H NMR (CDCl₃, 300 MHz) δ 1.42 (s, 9H), 3.35 (q, *J* = 6,1 Hz, 2H), 3.59 (t, *J* = 6 Hz, 2H), 3.68 (m, 4H), 3.85 (m, 4H), 4.98 (s, 1H), 6.19 (d, *J* = 8 Hz, 1H), 6.87 (s, 1H), 8.49 (d, *J* = 8,1 Hz, 1H) ppm. ¹³C NMR (CDCl₃, 75 MHz) δ 28.6, 41.1, 44.4, 69.5, 70.8, 71.2, 71.3, 78.8, 100.2, 137.9, 145.2, 145.6, 146.1, 156.1.

- 148
- 149
- 150

⁽S)-4-methyl-5-oxo-2-pentadecyl-2,5-dihydrofuran-3-carboxylic acid B-12 and (S)-2hexadecyl-4-methyl-5-oxo-2,5-dihydrofuran-3-carboxylic acid B-13:

^{141 (2-{2-[2-(7-}Nitro-benzo[1,2,5]oxadiazol-4-ylamino)-ethoxy]-ethoxy}-ethyl)-carbamic acid

151 N-(2-(2-(2-aminoethoxy))ethoxy)ethyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine 3:

This compound was prepared as published [17] and used for the next step without any furtherpurification.

154 155

156 *Probe B***-13** *NBD*:

To a solution of B-13 butyrolactone (44.6 mg, 0,122 mmol) and 1.28 equiv of TBTU (50.1 157 mg, 0,156 mmol) in anhydrous DMF (10 mL) under argon atmosphere, was added the NBD 158 159 spacer 3 (40 mg, 0.122 mmol, 1.0 equiv) and anhydrous DIEA (42.5 µL, 0.244 mmol, 2.0 equiv). After stirring overnight at room temperature, the reaction was quenched by adding 160 161 H₂O, this solution was then extracted with diethyl ether (3 x 50 mL) and once with ethyl 162 acetate. The combined organic layers were washed with brine, dried with MgSO₄ and 163 concentrated under vacuum. The residue was purified over preparative TLC (CH₂Cl₂/EtOH 95:5) to yield the desired compound. Yield = 63%; dark red solid. Rf (SiO₂, CH₂Cl₂/EtOH 164 (95:5) = 0,6. IR (ATR): v_{C-0} (ester) = 1133 cm⁻¹; v_{C-0} (lactone) = 1213 cm⁻¹; v_{C=C} (ar) = 165 1586 cm⁻¹; v _{C=C} = 1630 cm⁻¹; v _{C=O} (ester) = 1698 cm⁻¹; v _{C=O} (lactone) = 1734 cm⁻¹. ¹H 166 167 NMR (CDCl₃, 300 MHz) δ 0.87 (t, J = 6,7 Hz, 3H), 1.24 (m, 28H), 1.38 (m, 2H), 2.05 (s, 3H), 3.71 (m, 10H), 3.86 (t, J = 5,4 Hz, 2H), 5.15 (t, J = 5,8 Hz, 1H), 6.18 (d, J = 8,7 Hz, 168 1H), 6.42 (s, 1H), 6.82 (s, 1H), 8.46 (d, J = 8,7 Hz, 1H) ppm. ¹³C NMR (CDCl₃, 75 MHz) δ 169 10.8, 14.3, 21.2, 22.8, 25.1, 29.2, 29.3, 29.4, 29.5, 29.6, 29.7, 29.8, 29.8, 29.8, 30.2, 32.1, 170 32.9, 39.4, 43.6, 68.2, 69.7, 70.4, 70.6, 81.8, 99.1, 124.3, 129.1, 136.5, 143.8, 144.1, 153.8, 171 162.5, 171.3, 173.4 ppm. HRMS (ESI) m/z [M+Na]⁺ calcd. for C₃₄H₅₃N₅O₈Na 682,37918, 172 found 682.37920. Anal. Calcd. for C₃₄H₅₃N₅O₈ : C, 61,89; H, 8.10 ; N, 10.61. Found : C, 173 62.40; H, 8.06; N, 9.70. Calculated log P = 7.10. 174

175

176 *2.2. Bacterial strains*

We used in this study the oral bacteria, *Streptococcus gordonii* DL1 and *Porphyromonas gingivalis* ATCC 33277. We have grown them in an anaerobic environment (N₂-H₂-CO₂ [80:10:10]) at 37°C utilizing brain-heart infusion (BHI) medium (DIFCO, France) and blood Columbia agar plates (AES Chemunex, France) supplemented with hemin (5 μ g/mL) and menadione (1 μ g/mL) (Sigma Aldrich, France) [7].

183 2.3. Determination of the minimum inhibitory concentration and minimum bactericidal184 concentration

Broth microdilution test was done as described formerly [7]. In a nutshell, 1:2 serial 185 dilutions of the butyrolactone derivatives were done in BHI medium in 96-well plate (Sterile, 186 Flat bottom, with lid, Greiner Bio-one, Germany). Doxycycline antibiotic was used as a 187 positive control [18]. The wells were inoculated with 3x10⁷ CFU.ml⁻¹ of *P. gingivalis*. After 188 that, the plate is incubated anaerobically for 48 hours at 37°C. The clear well corresponding to 189 the lowest concentration was defined as the minimal inhibitory concentration or MIC. Then, 190 191 all the clear wells were spread on Columbia agar plates to be incubated for 5 days to uncover the minimal bactericidal concentration or MBC which is the lowest concentration plate with 192 193 no colonial growth. The experiment was repeated three times.

194

195 2.4. Cellular localization of butyrolactone derivatives in the oral bacteria

196 2.4.1. Confocal microscopy (CLSM)

After inoculating 1 mL of BHI medium to have finally 3 x 10⁷ CFU/mL of *S. gordonii* or *P. gingivalis*, they were incubated anaerobically for 18 or 48 hours, respectively. Then, the samples were centrifuged, the pellets were resuspended in PBS to be labeled by SYTO 40 and/or B-13-NBD for 15 minutes. After that, each condition was transferred into a microscopic glass slide and visualized under CLSM.

For CLSM images, Leica-SP8 scanning microscope (Leica Microsystems, Wetzlar, Germany) equipped with an inverted microscope (Fluorescence Microscopy Platform, IFR 140 GFAS, Université de Rennes 1) was used to visualize the slides *in situ*. The resonant option with 8000 Hertz was selected to capture the images utilizing the oil immersion objective lens (HC PL Apo 63X, 1.4 NA) where the numerical zoom was set at 8. The 405nm excitation laser and 430-440 nm band-pass emission filter were used for SYTO 40 and the 488-nm excitation laser and 506-535 nm band-pass emission filter in case of **B-13 NBD**.

The confocal microscopy was also used to evaluate the bacterial viability after their exposure to compound **B-13**. This viability was investigated by using two nucleic acidspecific dyes: SYTO 9 which is membrane-permeable, stains all cells and can be detected by green fluorescence, and propidium iodide (PI) which is membrane impermeable, stains cells with damaged membranes and gives red fluorescence. Bacteria treated with **B-13** were visualized *in situ* utilizing a Leica TCS-SP8 confocal laser scanning microscope (Leica Microsystems, Wetzlar, Germany) equipped with an inverted microscope (Fluorescence Microscopy Platform, IFR 140 GFAS, Université de Rennes I). For an entire bacterial detection with the dyes, specific excitation lasers and emission filters were used. The 488-nm excitation laser and 506-539 nm band-pass emission filter were utilized for SYTO 9 and the 561-nm excitation laser and 600-700 nm band-pass emission filter in case of PI.

Image acquisition and microscope piloting were done by the Leica software (LAS AF V.2.2.1), and ImageJ software V1.48m (National Institute of Health) was used to analyze the images.

223 2.4.2. HPLC-DAD analysis

In a 96-well plate (Sterile, Flat bottom, with lid, Biolite, Thermo Fisher Scientific, Korea) 224 containing 100 µL of BHI with or without **B-13**, 100 µL of *S. gordonii* were added into each 225 well to have a final concentration of 3 x 10⁷ CFU/mL. A replicate for each condition was 226 prepared. After incubation under anaerobic condition at 37°C for 18 hours, the contents of 227 the MIC/2 wells were collected in an Eppendorf and extracted using an optimized protocol of 228 that described by Leejae et al. 2013 [19]. Briefly, the samples were centrifuged at 5000 rpm 229 for 10 minutes at 4 °C. The pellets obtained were washed 2 times with a buffer containing 230 (10 mM Tris.HCl of pH = 8, 0.1 mM EDTA, 1 mM DTT, 5% ethanol, and 50 mM NaCl). 231 Then, the pellets were lysed by sonication on ice for 5-10 min to be centrifuged at 5000 rpm 232 for 10 min at 4°C. Supernatants comprising the cytoplasm and the pellets containing the cell 233 wall and cell membrane were separated to be extracted by ethyl acetate. The organic upper 234 layer was transferred into a new tube to be washed with distilled water. Again, the upper 235 layer was transferred into another tube in which anhydrous sodium sulfate was added. The 236 remaining liquid was finally transferred into a new tube and evaporated to dryness for the 237 powder to be dissolved in THF. HPLC analysis were performed on a Prominence Shimadzu 238 HPLC system (Marne La Vallée, France) equipped with a C18 hypersil Gold aQ column 239 (250 x 4.6 mm, 5 µm, Thermo Scientific) and consisting of a binary pump (LC-20ADSP), a 240 surveyor autosampler (SIL-20AHT) and a diode array detector (SPD-M20A). The mobile 241 phase consisted of (H₂O + 0.1% HCOOH) as solvent A and (ACN + 0.1% HCOOH) as 242 solvent B with gradient: 0% of B during 5 min, 0%-100% of B during 5 min, 100% of B 243 during 5 min, 100%–0% of B during 5 min, 0% of B during 10 min. The flow rate was 1 244 mL/min and 20 µL of each sample were injected. DAD data were recorded at 228 and 254 245

nm and absorption spectra (210-400 nm) were recorded each second. The two samples, the 246 pellet, and supernatant of each condition, had their own HPLC chromatograms allowing us to 247 determine in which one (cell wall/cytoplasm) the butyrolactone was detected. Identification 248 of B-13 in the samples was done by comparison of its retention time and UV-spectra with the 249 standard under the same chromatographic conditions. 250

251 2.4.3. Transmission electron microscopy (TEM):

Following overnight incubation, treated or untreated bacteria were collected, 252 transferred to Eppendorf tubes and washed three times in Cacodilic buffer (0.15 M, pH 7.4). 253 Fractions of bacterial suspension were fixed at 4°C for 60 min with 2% glutaraldehyde in 254 0.15 M Cacodilic buffer to be washed three times in the same buffer. Cells were post-fixed in 255 1% OsO4 for 60 min at 4°C, rinsed in Cacodilic buffer and embedded in 2% Low melting 256 agar (Sigma). After the dehydration series in acetone, the cells samples were embedded in 257 conventional EPON (EMS 1420) and then polymerized at 60°C for 48h. Resins blocks were 258 sectioned into 80 nm ultrathin sections using ultramicrotome LEICA UC7. These sections 259 260 were mounted on copper grids and stained. Grids were observed using a TEM JEOL-JEM 261 1400 (Jeol Ltd, Tokyo, Japan) at an accelerating voltage of 120 kV and equipped with a Gatan Inc. Orius 1000 camera. 262

- 263
- 264

3. RESULTS AND DISCUSSION

3.1. Effect of butyrolactone analogs on the growth of P. gingivalis planktonic cells 265

The synthesized butyrolactones were shown to be potentially active against P. 266 gingivalis where the COOH-containing compounds carrying an aliphatic chain with a minimal 267 number of 13 carbon atoms were the best (Table 1). **B-7** was the least active with MIC = 75268 269 μ g ml⁻¹ and no MBC. It was followed by the unsaturated compounds (B-3 and B-4) or saturated compounds substituted with a hydroxyl (B-1 and B-2), or a vinyl group (B-5 and B-270 6) which exhibited moderate activity. The activity increased to reach MICs = 0.037 and 0.293271 μ g ml⁻¹ and MBCs = 1.17 and 0.586 μ g ml⁻¹ for **B-12** and **B-13**, respectively. These latter 272 butyrolactones possess a conjugated carboxylic acid group and the longer aliphatic chains. 273 They were even stronger than the reference antibiotic, doxycycline which presented an MIC = 274 0.13 µg ml⁻¹ and no MBC. It is worth noting that **B-12** was more efficient than doxycycline 275 by about 3 times comparing their MICs and much more effective regarding their MBCs 276

Compound	MIC (µg/mL)	MBC (µg/mL)
B-1	9.38	37.5
B-2	37.5	150
B-3	4.69	37.5
B-4	4.69	75
B-5	37.5	75
B-6	2.34	75
B-7	75	>i
B-8	9.38	150
B-9	37.5	150
B-10	0.073	9.38
B-11	0.586	4.69
B-12	0.037	1.17
B-13	0.293	0.586
Doxycycline	0.13	>i

Table 1. MIC and MBC of butyrolactones against *P. gingivalis* by broth microdilution

279


280 3.2. Fluorescent B-13 butyrolactone adheres to S. gordonii membrane

Previously, we have demonstrated that lichen butyrolactone derivatives such as B-13
inhibit two oral bacteria *S. gordonii* [7] and *P. gingivalis* (unpublished results).

283 However, further studies are needed to determine the putative mechanisms for their antimicrobial activity. We were therefore interested in preparing a fluorescent tool to try to 284 285 elucidate their mechanism. We envisioned that this could be accomplished by using NBD, a commonly used fluorescent probe as fluorophore and a pegylated diamine as a linker. So, we 286 synthesized the NBD-tagged butyrolactone B-13 (Scheme 1). Based on a reported 287 methodology [17], the NBD-based probe 3 was obtained by anchoring N-Boc monoprotected 288 289 Pegylated diamine linker 1 to chloro-NBD in the presence of cesium carbonate in acetonitrile followed by TFA mediated amine deprotection. Finally, this fluorescent probe was coupled 290 to the active substrate. For this last step, we selected a peptidic coupling reaction between the 291

²⁷⁸ >i: greater than the initial concentration

probe and B-13 (step 3). This was carried out in the presence of TBTU and DIEA in
anhydrous DMF. The final B-13 NBD compound was thus obtained with a yield of 63%.



- 294 295
- 296

Scheme 1. Synthesis of B-13 NBD fluorescent probe

In such an approach using a fluorescent tool, one critical point is the good positioning 297 298 of the probe in the active compound so that the biological activity is maintained. So, B-13 **NBD** was evaluated (MIC = 37.5 μ g ml⁻¹) and compared to **B-13** for its antimicrobial 299 activity. Notably, the conjugation of NBD to B-13 did not eliminate their biological activity 300 as their antimicrobial activity against S. gordonii was seen. Zhao et al. 2016 [20] also have 301 shown that NBD is a highly tolerated fluorescence label and Matijašić et al. in 2012 [21] 302 have demonstrated that 9a-NBD-azithromycin has antimicrobial properties comparable to 303 azithromycin. In order to compare the polarity of the probe and the active B-12 and B-13 304 compounds, their log P values have been calculated using ALOGPS 2.1 software giving a 305 prediction of their relative lipophilicity. Regarding their Log P values (B-13 NBD: $\log P =$ 306 7.10; **B-12**: $\log P = 7.29$ and **B-13**: $\log P = 7.67$), the three compounds appear to be highly 307 lipophilics and display the same polarity. So the probe could be used as model to support the 308 direct binding of **B-12** and **B-13** to the bacterial membrane. 309

After that, we have used B-13 NBD, NBD (7-nitrobenz-2-oxa-1,3-diazole) is a small size 310 fluorescent probe originally introduced to label proteins through binding to their hydrophobic 311 region, to investigate the cellular localization of B-13 in S. gordonii by confocal laser 312 scanning microscopy (CLSM). Confocal microscopic images of S. gordonii following the 313 treatment of B-13 NBD showed green fluorescence (Fig. 2) which indicated considerable 314 binding of this compound onto the bacteria, as seen by the presence of green fluorescence on 315 cell membranes. The green fluorescence has surrounded the bacterial DNA stained in blue 316 with SYTO 40, suggesting a strong localization in the cell wall. Tripathi et al. 2015 used this 317

NBD fluorescent probe to label IsCT, antimicrobial peptide, and its analogs [22]. They showed that some IsCT-NBD labelled versions were accumulated onto the bacterial membrane, others were translocated throught *E. coli* membrane and were localized in the cytoplasm. This study demonstrated that NBD did not prevent localization of molecules in cytoplasm

323






Fig. 2. Localization of fluorescently labeled B-13 NBD in *S. gordonii* and *P. gingivalis* by confocal microscopy. The bacterial DNA is stained by SYTO 40 in blue and B-13 NBD adhered to the bacterial surface and appears in green. Bars represent 2µm.

328

Cellular dysfunctions can result from the interaction of an antimicrobial with the 329 microbial cell membrane [23]. The antimicrobial can only attach to the cell membrane and 330 alter its structure, permeability, and/or transport activity. On the other hand, the antimicrobial 331 can follow another pathway. After binding the cell membrane, it may penetrate inside the 332 cells and affect vital cellular functions. To determine the antibacterial mechanisms of B-13 in 333 S. gordonii, localization of B-13 in the bacteria was performed after incubating the latter with 334 the compound for 1 and 18h. Lysed bacteria were centrifuged and their cell wall and 335 membrane pellet (Fig. 3a) and cytoplasmic supernatant (Fig. 3b) fractions were analyzed 336 using HPLC. Chromatograms in Figure 3 indicated that the compound was clearly visualized 337

only in the cell wall and membrane fraction of the treated cells in the same manner as the control **B-13** after 1h of incubation. After 18h of treatment, a low level of **B-13** was detected in the cell membrane. This signal decrease of the compound may be caused by the degradation or the release by bacteria of this butyrolactone. In contrast, **B-13** was not detected in the cytoplasm fraction. This kinetic study suggests that **B-13** binds the membrane and does not cross to the cytoplasm.







Fig. 3. Localization of B-13 in *S. gordonii* using HPLC method. After incubation with B-13, *S. gordonii* was lysed, and the cell wall and cell membrane were separated from the cytoplasm
by centrifugation. (a) HPLC analysis of cell wall and membrane; (b) HPLC analysis of
cytoplasm. B-13 was detected in the cell wall and membrane fraction of lysed *S. gordonii*. B13 as a reference (1), *S. gordonii* incubated with B-13 for 1h (2) or 18h (3), *S. gordonii*incubated alone for 1h (4) or 18h (5).

351

352 *3.3 B-13 Butyrolactone induced cell wall disruption of S. gordonii*

To obtain a deeper insight into the mode of action of **B-13**, the morphology of *S*. *gordonii* was visualized by transmission electron microscopy (TEM) after treatment with this

compound (Fig. 4). Untreated bacteria appeared intact with a typically delimited cell wall 355 and well-defined membrane, and a cytoplasmic content with few electron-dense areas. 356 Treatment with doxycycline, the reference antibiotic [18], caused cytoplasmic alterations as 357 suggested by the presence of round bodies in the cytoplasm with a similar electron density 358 like clear vesicles. However, in presence of B-13, the bacteria appeared lysed with broken 359 walls and membranes, and heterogeneous electron density zones in the cytoplasm (Fig. 4). 360 The cells showed aberrant morphology; they were cracked and ruptured leading to their 361 death. In some cells, the externalization of cytoplasmic material could be seen by the way of 362 363 vesicles and rupture of the cell. Altogether, the results suggested that B-13 inflicted considerable damage to S. gordonii membrane and this membrane disruption property could 364 365 be the basis of the antibacterial activity of this compound.



366

Fig. 4. Transmission electron micrographs of *S. gordonii*. B-13, as B-12, disrupted *S. gordonii*cell wall (as indicated by black arrows).

Furthermore, we have counted the damaged bacterial cells upon treatment with butyrolactones or doxycycline in three random regions from the electron micrographs of each condition and calculated their percentages (Table 2). *P. gingivalis* was shown to be more sensitive than *S. gordonii*, and this coincides with our results from the microdilution test. Butyrolactones had similar values which were higher than doxycycline by 1.5 to 2 times.

374

Table 2. Percentage of damaged bacterial cells upon treatment with butyrolactones or

	S. gordonii	P. gingivalis
B-12	58.5±1.3	92.5±2.8
B-13	55.7±1.6	86.1±3.1
Doxycyline	32.6±2.6	66.4±1.2

377 doxycycline (enumerated in the transmission electron micrographs).

CLSM analysis was used to provide further confirmation of our hypothesis on this 378 membrane disruption. In order to follow permeability modification due to B-13 exposure, we 379 monitored the fluorescence intensity of bacterial culture mixed with propidium iodide (PI) 380 and SYTO 9 [24]. SYTO 9 can penetrate intact or damaged membranes giving green 381 382 fluorescence, however, PI fluoresces in red and can only penetrate damaged membranes. As a result, the dead cells have appeared nearly in orange color due to the presence of the two 383 384 labels. As shown in figure 5, untreated control S. gordonii cells appeared predominantly green (demonstrating living cells); whereas the B-13 treated cells appeared substantially red, 385 386 indicating the high permeability of PI dye and that most of the cells were dead. This result confirmed that B-13 had a destructive effect on the cell membranes where the majority of the 387 388 bacteria were dead.

 S. gondonii
 S. gondonii

 S. gondonii</td


Fig. 5. *S. gordonii* cell suspension, untreated or treated with B-13, stained with SYTO 9 and
PI, and analyzed by CLSM. Cells with intact membranes were stained with green
fluorescence, whereas cells with ruptured membranes were stained with red fluorescence. The
overlap of the two stains appears in orange. Bars represent 10µm.

394

395 3.4 B-13 Butyrolactone has also disrupted the Gram-negative bacterial membrane of P.
396 gingivalis

In order to determine if its antimicrobial potential is influenced by the cell wall 397 composition of the microorganisms, we have investigated the effect of **B-13** on *P. gingivalis*, 398 a Gram-negative strain. When we used B-13 NBD on P. gingivalis (Fig. 2), we have 399 observed a prominent green fluorescence on cell membranes. Figure 6 showed TEM 400 micrograph of P. gingivalis control with a typical cell wall, outer and cytoplasmic 401 membrane, periplasmic space and cytoplasmic content with few electron-dense areas. When 402 403 P. gingivalis was treated with B-13, cells were damaged showing either localized or complete separation of the cell membrane from the cell wall. The cellular degradation was 404 405 also accompanied by electron-translucent cytoplasm and cellular disruption in the damaged cells. These differences in structure, thickness, and composition of the cell can explain why 406 Gram-positive S. gordonii were less inhibited and Gram-negative P. gingivalis showed 407 substantial inhibition even at lower antibiotic concentration. 408

409



411 Fig. 6. Transmission electron micrographs of *P. gingivalis*. B-13, as B-12, disrupted *P. gingivalis* cell wall (as indicated by black arrows).

414

3.5 B-13 Butyrolactone analog, B-12, has also disrupted the membrane of oral bacteria

In order to determine if this membrane disruption is specific to the synthesized butyrolactone, we have used an analog of **B-13**, **B-12** with a shorter aliphatic chain (Fig. 1), which we have already described in Sweidan et al. 2016 [7]. Electron Micrographs of *S. gordonii* or *P. gingivalis* treated with **B-12** showed broken membrane and dead bacteria (Fig. 4 and Fig. 6). However, as for **B-13**, we found that the effect of **B-12** is also more active against Gram-negative as seen by the formation of unwinded structures in the cell wall, irregularly shaped cells, and scratched cell surface of *P. gingivalis* (Fig. 6).

The finding that **B-12** has the ability to break and damage the bacterial membrane leads to propose that the bactericidal effect of our synthesized butyrolactones is based on destroying the cell surface of bacteria.

425

426 **4.** Conclusion

427 S. gordonii and P. gingivalis are oral bacteria initiating the formation of dental plaques 428 contributing in turn to the onset of dental caries and periodontal diseases as well as their progression [10]. We have previously demonstrated that these bacteria are sensitive to new 429 430 drugs which are of natural origin as they are derived from lichen secondary metabolites [7,25]. However, its antibacterial mechanisms are still unknown. By using the compound (B-431 432 13) which is one of the most active butyrolactones series synthesized based on the natural compound, lichesterinic acid, we have shown that this compound has bound to the bacterial 433 434 surface and induced membrane modification breaking the cell wall and releasing the 435 cytoplasmic constituents leading to bacterial death. These results suggested that its 436 antimicrobial potential is influenced by the composition of the cell wall of the 437 microorganisms [26].

This study shows for the first time the mechanism of action of synthesized butyrolactones, analogs of lichesterinic acid. To our knowledge, there are only two studies on the mechanism of action of lichen-derived compounds [27], [3]. Gupta et al. (2012) demonstrated that usnic acid, a commonly occurring polyphenolic compound in many species of lichens, can destabilize the membrane integrity of Methicillin-Resistant *Staphylococcus aureus* (MRSA) [27]. Shrestha et al. 2016 demonstrated also that *L. vulpina* extracts disrupted the integrity of MRSA membranes and targeted its cell division processes
in MRSA [28]. These studies have only investigated Gram-positive strains whereas both
Gram types were investigated in the present study.

Our study opens the door for future mechanistic research on lichen secondary 447 metabolites which will give a better understanding of lichen as an association of fungus and 448 alga and/or cyanobacterium forming a symbiotic organism and how to use its secondary 449 metabolites as antibiotics. In addition, the structures of the butyrolactone analogs are 450 different from those of all the antibiotics discovered to date including the cell wall-targeting 451 452 ones. This fact supported by the way these compounds target the bacteria as described in our study, may introduce a new generation of antibiotics with a new mode of action. However, to 453 better develop a new antibiotic, it is necessary to make further investigations on lichen 454 455 secondary metabolites in general and **B-13** in particular.

456 **Conflicts of interest**

- 457 The authors declare no conflicts of interest.
- 458

459 Acknowledgments

460 We would like to acknowledge C. Le Lann, (NUMECAN – Rennes I University, France),

- 461 Marie Thérèse Lavault (Plateforme microscopie électronique MRic, Campus Santé, Rennes
- 1, France) and Stephanie Dutertre (Platforme Microscopie, Biosit, Campus Santé, Rennes 1,
- 463 France) for their technical help in CLSM.
- 464 Funding

465

Rennes I University, UMR CNRS 6226 (France), and Association of Specialization and
Scientific Orientation (Lebanon) were behind supporting this research.

- 468
- 469
- 470

471

473 **REFERENCES**

- 474 [1] O. Özgenç, Methodology in improving antibiotic implementation policies, World J.
 475 Methodol. 6 (2016) 143–153. doi:10.5662/wjm.v6.i2.143.
- 476 [2] A. Borges, A. Abreu, C. Dias, M. Saavedra, F. Borges, M. Simões, New perspectives on
 477 the use of phytochemicals as an emergent strategy to control bacterial infections
 478 including biofilms, Molecules. 21 (2016) 877. doi:10.3390/molecules21070877.
- 479 [3] G. Shrestha, L.L. St. Clair, Lichens: a promising source of antibiotic and anticancer
 480 drugs, Phytochem. Rev. 12 (2013) 229–244. doi:10.1007/s11101-013-9283-7.
- 481 [4] J. Boustie, M. Grube, Lichens-a promising source of bioactive secondary metabolites,
 482 Plant Genet. Resour. Charact. Util. 3 (2005) 273–287. doi:10.1079/PGR200572.
- V. Shukla, G.P. Joshi, M.S.M. Rawat, Lichens as a potential natural source of bioactive compounds: a review, Phytochem. Rev. 9 (2010) 303–314. doi:10.1007/s11101-010-9189-6.
- 486 [6] M. Bačkorová, R. Jendželovský, M. Kello, M. Bačkor, J. Mikeš, P. Fedoročko, Lichen
 487 secondary metabolites are responsible for induction of apoptosis in HT-29 and A2780
 488 human cancer cell lines, Toxicol. Vitro Int. J. Publ. Assoc. BIBRA. 26 (2012) 462–468.
 489 doi:10.1016/j.tiv.2012.01.017.
- A. Sweidan, M. Chollet-Krugler, P. van de Weghe, A. Chokr, S. Tomasi, M. Bonnaure-490 [7] Mallet, L. Bousarghin, Design, synthesis and biological evaluation of potential 491 antibacterial butyrolactones. Bioorg. Med. Chem. 24 492 (2016)5823-5833. doi:10.1016/j.bmc.2016.09.040. 493
- [8] K.Y. How, K.P. Song, K.G. Chan, Porphyromonas gingivalis: An Overview of
 Periodontopathic Pathogen below the Gum Line, Front. Microbiol. 7 (2016) 53.
 doi:10.3389/fmicb.2016.00053.
- P.P.C. Pita, J.A. Rodrigues, C. Ota-Tsuzuki, T.F. Miato, E.G. Zenobio, G. Giro, L.C.
 Figueiredo, C. Gonçalves, S.A. Gehrke, A. Cassoni, J.A. Shibli, Oral Streptococci
 Biofilm Formation on Different Implant Surface Topographies, BioMed Res. Int. 2015
 (2015) 159625. doi:10.1155/2015/159625.
- [10] H.M. Ng, L.X. Kin, S.G. Dashper, N. Slakeski, C.A. Butler, E.C. Reynolds, Bacterial
 interactions in pathogenic subgingival plaque, Microb. Pathog. 94 (2016) 60–69.
 doi:10.1016/j.micpath.2015.10.022.
- 504 [11] F. Guilhelmelli, N. Vilela, P. Albuquerque, L. da S. Derengowski, I. Silva-Pereira, C.M.
 505 Kyaw, Antibiotic development challenges: the various mechanisms of action of
 506 antimicrobial peptides and of bacterial resistance, Front. Microbiol. 4 (2013) 353.
 507 doi:10.3389/fmicb.2013.00353.
- 508 [12] J. van Heijenoort, Recent advances in the formation of the bacterial peptidoglycan
 509 monomer unit, Nat. Prod. Rep. 18 (2001) 503-519.
- 510 [13] A. Typas, M. Banzhaf, C.A. Gross, W. Vollmer, From the regulation of peptidoglycan
 511 synthesis to bacterial growth and morphology, Nat. Rev. Microbiol. 10 (2011) 123–136.
 512 doi:10.1038/nrmicro2677.
- 513 [14] J.G. Hurdle, A.J. O'Neill, I. Chopra, R.E. Lee, Targeting bacterial membrane function:
 514 an underexploited mechanism for treating persistent infections, Nat. Rev. Microbiol. 9
 515 (2011) 62–75. doi:10.1038/nrmicro2474.
- 516 [15] B. Kouidhi, Y.M.A. Al Qurashi, K. Chaieb, Drug resistance of bacterial dental biofilm
 517 and the potential use of natural compounds as alternative for prevention and treatment,
 518 Microb. Pathog. 80 (2015) 39–49. doi:10.1016/j.micpath.2015.02.007.
- 519 [16] K. Lewis, Platforms for antibiotic discovery, Nat. Rev. Drug Discov. 12 (2013) 371–
 520 387. doi:10.1038/nrd3975.

- [17] S. Noël, L. Guillon, I.J. Schalk, G.L.A. Mislin, Synthesis of Fluorescent Probes Based
 on the Pyochelin Siderophore Scaffold, Org. Lett. 13 (2011) 844–847.
 doi:10.1021/ol1028173.
- [18] J.H. Park, J.-K. Lee, H.-S. Um, B.-S. Chang, S.-Y. Lee, A periodontitis-associated
 multispecies model of an oral biofilm, J. Periodontal Implant Sci. 44 (2014) 79.
 doi:10.5051/jpis.2014.44.2.79.
- 527 [19] S. Leejae, P.W. Taylor, S.P. Voravuthikunchai, Antibacterial mechanisms of
 528 rhodomyrtone against important hospital-acquired antibiotic-resistant pathogenic
 529 bacteria, J. Med. Microbiol. 62 (2013) 78–85. doi:10.1099/jmm.0.049205-0.
- [20] C. Zhao, A. Fernandez, N. Avlonitis, G. Vande Velde, M. Bradley, N.D. Read, M.
 Vendrell, Searching for the Optimal Fluorophore to Label Antimicrobial Peptides, ACS
 Comb. Sci. 18 (2016) 689–696. doi:10.1021/acscombsci.6b00081.
- [21] M. Matijašić, V. Munić Kos, K. Nujić, S. Čužić, J. Padovan, G. Kragol, S. Alihodžić, B.
 Mildner, D. Verbanac, V. Eraković Haber, Fluorescently labeled macrolides as a tool for
 monitoring cellular and tissue distribution of azithromycin, Pharmacol. Res. 66 (2012)
 332–342. doi:10.1016/j.phrs.2012.06.001.
- 537 [22] J.K. Tripathi, M. Kathuria, A. Kumar, K. Mitra, J.K. Ghosh, An unprecedented
 538 alteration in mode of action of IsCT resulting its translocation into bacterial cytoplasm
 539 and inhibition of macromolecular syntheses, Sci. Rep. 5 (2015) 9127.
 540 doi:10.1038/srep09127.
- [23] J.A. Tennessen, Molecular evolution of animal antimicrobial peptides: widespread
 moderate positive selection, J. Evol. Biol. 18 (2005) 1387–1394. doi:10.1111/j.14209101.2005.00925.x.
- 544 [24] D.J. Arndt-Jovin, T.M. Jovin, Fluorescence labeling and microscopy of DNA, Methods
 545 Cell Biol. 30 (1989) 417–448.
- 546 [25] B. Gökalsın, N.C. Sesal, Lichen secondary metabolite evernic acid as potential quorum
 547 sensing inhibitor against <i>Pseudomonas aeruginosa<i/>, World J. Microbiol.
 548 Biotechnol. 32 (2016). doi:10.1007/s11274-016-2105-5.
- [26] N. Malanovic, K. Lohner, Gram-positive bacterial cell envelopes: The impact on the activity of antimicrobial peptides, Biochim. Biophys. Acta. 1858 (2016) 936–946.
 doi:10.1016/j.bbamem.2015.11.004.
- [27] V.K. Gupta, S. Verma, S. Gupta, A. Singh, A. Pal, S.K. Srivastava, P.K. Srivastava, S.C.
 Singh, M.P. Darokar, Membrane-damaging potential of natural L-(-)-usnic acid in *Staphylococcus aureus*, Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin.
 Microbiol. 31 (2012) 3375–3383. doi:10.1007/s10096-012-1706-7.
- [28] G. Shrestha, A. Thompson, R. Robison, L.L. St Clair, Letharia vulpina, a vulpinic acid containing lichen, targets cell membrane and cell division processes in methicillinresistant *Staphylococcus aureus*, Pharm. Biol. 54 (2016) 413–418. doi:10.3109/13880209.2015.1038754.

Figures captions

Scheme 1. Synthesis of B-13 NBD fluorescent probe.

Fig. 1. Chemical structures of B-12, B-13, and B-13 NBD.

Fig. 2. Localization of fluorescently labeled **B-13 NBD** in *S. gordonii* and *P. gingivalis* by confocal microscopy. The bacterial DNA is stained by SYTO 40 in blue and **B-13 NBD** adhered to the bacterial surface and appears in green. Bars represent 2μm.


Fig. 3. Localization of B-13 in *S. gordonii* using HPLC method. After incubation with B-13, *S. gordonii* was lysed, and the cell wall and cell membrane were separated from the cytoplasm by centrifugation. (a) HPLC analysis of cell wall and membrane; (b) HPLC analysis of cytoplasm.
B-13 was detected in the cell wall and membrane fraction of lysed *S. gordonii*. B-13 as a reference (1), *S. gordonii* incubated with B-13 for 1h (2) or 18h (3), *S. gordonii* incubated alone for 1h (4) or 18h (5).


Fig. 4. Transmission electron micrographs of *S. gordonii*. **B-13**, as **B-12**, disrupted *S. gordonii* cell wall (as indicated by black arrows).


Fig. 5. *S. gordonii* cell suspension, untreated or treated with **B-13**, stained with SYTO 9 and PI, and analyzed by CLSM. Cells with intact membranes were stained with green fluorescence, whereas cells with ruptured membranes were stained with red fluorescence. The overlap of the two stains appears in orange. Bars represent 10µm.

Fig. 6. Transmission electron micrographs of *P. gingivalis*. **B-13**, as **B-12**, disrupted *P. gingivalis* cell wall (as indicated by black arrows).

Scheme 1








B-13


B-12



B-13 NBD

Fig. 1.

SYTO 40






Fig. 2.




Fig. 3.




Fig. 4.




Fig. 5.

Compound	MIC (µg/mL)	MBC (µg/mL)
B-1	9.38	37.5
B-2	37.5	150
B-3	4.69	37.5
B-4	4.69	75
B-5	37.5	75
B-6	2.34	75
B-7	75	>i
B-8	9.38	150
B-9	37.5	150
B-10	0.073	9.38
B-11	0.586	4.69
B-12	0.037	1.17
B-13	0.293	0.586
Doxycycline	0.13	>i

Table 1. MIC and MBC of butyrolactones against *P. gingivalis* by broth microdilution

>*i*: greater than the initial concentration

Table 2. Percentage of damaged bacterial cells upon treatment with butyrolactones or doxycycline (enumerated in the transmission electron micrographs).

	S. gordonii	P. gingivalis
B-12	58.5±1.3	92.5±2.8
B-13	55.7±1.6	86.1±3.1
Doxycyline	32.6±2.6	66.4±1.2